Gilead joins the line­up of big bio­phar­ma part­ners to al­ly with Ver­i­ly — this time fo­cused on im­munol­o­gy

Ver­i­ly Life Sci­ences will put its im­munol­o­gy plat­form Im­munoscape to work for Gilead, prob­ing the im­mune cells of pa­tients suf­fer­ing from rheuma­toid arthri­tis, in­flam­ma­to­ry bow­el dis­ease and lu­pus in search of pa­tient sub­types more like­ly to re­spond to the drugs Gilead has in the pipeline, or the ones it can de­vel­op in the fu­ture.

For Ver­i­ly, part of the com­put­er con­glom­er­ate Al­pha­bet, this is a chance to un­roll the plat­form out in the first large scale demon­stra­tion pro­gram of what it’s ca­pa­ble of do­ing. Gilead’s re­port­ed­ly agreed to pay up to $90 mil­lion for the three-year al­liance, and they can get start­ed on the mid- and late-stage stud­ies un­der­way in its im­munol­o­gy pipeline — topped by its fo­cus on fil­go­tinib.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER